The third LBO of Acteon marks a definitive strategic shift toward institutional global leadership, orchestrated by Bridgepoint Development Capital alongside Raise Investissement and Euro Private Equity. The strategic rationale for this transaction centers on an "innovation-acceleration" play, merging the group’s industry-leading technical operational depth in ultrasonics with the sponsor’s extensive international commercial infrastructure. This structural alignment provides the organization with the scientific talent and logistical hardware required to address the increasing complexity of the global digital dentistry market. This operation allows the group to execute a definitive structural expansion of its product suite, particularly through a renewed emphasis on research and development following several years of stabilization. By incorporating the sponsor’s strategic discipline, the group is now positioned to leverage its recognized leadership in high-frequency imaging to deepen its presence in high-stakes markets such as North America and Asia.

Acteon is a France company specialized in Dental Technology. The organization has built its name as a high-fidelity provider of specialized medical devices, particularly leading the field in ultrasound surgery and digital medical imaging. Instead of producing generic dental tools, they thrive on a philosophy of clinical precision, offering innovative hardware that enables dentists and surgeons to perform minimally invasive procedures with superior imaging clarity. Their growth is currently fueled by a rigorous focus on new product development, a shift that has allowed them to break out of historical stagnation and capture significant market share in fast-growing dental tech segments.